Improving the tolerability of osimertinib by identifying its toxic limit

Improving the tolerability of osimertinib by identifying its toxic limit

Background: Osimertinib is the cornerstone in the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer (NSCLC). Nonetheless, ±25% of patients experience severe treatment-related toxicities. Currently, it is impossible to identify patients at risk of severe toxicity before...

Full description

Bibliographic Details
Main Authors: Bram C. Agema, G. D. Marijn Veerman, Christi M. J. Steendam, Daan A. C. Lanser, Tim Preijers, Cor van der Leest, Birgit C. P. Koch, Anne-Marie C. Dingemans, Ron H. J. Mathijssen, Stijn L. W. Koolen
Format: Article
Language:English
Published: SAGE Publishing 2022-05-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359221103212

Internet

https://doi.org/10.1177/17588359221103212

Similar Items